Gitnux/Report 2026

Roofie Statistics

118Statistics
5Sections
1Visuals
7mRead
July 13, 2026Updated
Roofie Statistics
Karl BeckerWritten by Karl Becker·Edited by Jonathan Hale·Fact-checked by Sarah Mitchell
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 36 days

Key Takeaways

  • Flunitrazepam causes respiratory depression in 25% of high-dose users.
  • Overdose fatality rate with Roofie alone is low, <1%, but 10% with alcohol.
  • Amnesia duration averages 8-12 hours post-ingestion.
  • Flunitrazepam, commonly known as Roofie, has a molecular weight of 313.3 g/mol.
  • The chemical formula of Roofie (flunitrazepam) is C16H12FN3O3.
  • Roofie is a benzodiazepine with a nitro group at the 7-position, enhancing its potency.
  • Roofie banned for manufacture/import in US since 1996.
  • Classified as Schedule IV under US Controlled Substances Act.
  • Possession penalty in US: up to 3 years prison first offense.
  • Roofie was first synthesized in 1963 by Hoffman-La Roche.
  • Flunitrazepam is prescribed for severe insomnia unresponsive to other treatments.
  • Recommended dose for insomnia is 1-2 mg at bedtime.
  • Roofie involved in 1% of drug-facilitated assaults reported in US 1996-2000.
  • In 1990s, 1-2% of US college students reported lifetime Roofie use.
  • Street price of Roofie in US is $2-10 per tablet.

Related reading

01 · Category

Adverse Effects And Health Risks22 stats

01
Flunitrazepam causes respiratory depression in 25% of high-dose users.
02
Overdose fatality rate with Roofie alone is low, <1%, but 10% with alcohol.
03
Amnesia duration averages 8-12 hours post-ingestion.
04
40% of users experience next-day drowsiness.
05
Paradoxical aggression occurs in 1-2% of patients.
06
Dependency risk after 4 weeks: 15-30%.
07
Withdrawal seizures in 5% of abrupt stoppers.
08
Hypotension seen in 20% of IV administrations.
09
Anterograde amnesia incidence 60% at 2 mg dose.
10
Liver enzyme elevation in 2% chronic users.
11
Falls and hip fractures increased 3-fold in elderly users.
12
Respiratory arrest risk 5x higher with opioids combo.
13
Cognitive impairment persists 24 hours in 50%.
14
Hallucinations in 0.5% of therapeutic doses.
15
QT prolongation rare, <1% cases.
16
Neonatal withdrawal if used in pregnancy: 10% incidence.
17
Muscle weakness in 30% next day.
18
Overdose symptoms resolve in 95% with supportive care.
19
Flumazenil reverses effects in 80% of cases.
20
Chronic use linked to 20% depression risk increase.
21
GI upset in 10% of users.
22
Driving impairment equivalent to 0.1% BAC.

02 · Category

Chemical And Pharmacological Properties30 stats

01
Flunitrazepam, commonly known as Roofie, has a molecular weight of 313.3 g/mol.
02
The chemical formula of Roofie (flunitrazepam) is C16H12FN3O3.
03
Roofie is a benzodiazepine with a nitro group at the 7-position, enhancing its potency.
04
The melting point of flunitrazepam is 210-212°C.
05
Roofie exhibits high lipophilicity, with a logP value of 2.2.
06
Flunitrazepam has a pKa of 1.82 for its conjugate acid.
07
The elimination half-life of Roofie ranges from 18 to 26 hours in healthy adults.
08
Peak plasma concentration of oral flunitrazepam occurs within 1-3 hours post-dose.
09
Bioavailability of Roofie tablets is approximately 64-77%.
10
Flunitrazepam is extensively metabolized by CYP3A4 in the liver.
11
The volume of distribution for Roofie is 3.1 L/kg.
12
Protein binding of flunitrazepam is 85%.
13
Roofie binds with high affinity to the benzodiazepine site on GABA-A receptors.
14
Ki value for flunitrazepam at BZ1 receptor subtype is 1.1 nM.
15
Flunitrazepam is 7-10 times more potent than diazepam.
16
The active metabolite 7-aminoflunitrazepam has a half-life of 36 hours.
17
Roofie solubility in water is 0.3 mg/mL at 25°C.
18
Flunitrazepam is available in 1 mg and 2 mg tablet strengths.
19
The drug's IUPAC name is 5-(2-fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one.
20
Roofie undergoes N-demethylation as a primary metabolic pathway.
21
Flunitrazepam has an onset of action within 15-30 minutes when taken orally.
22
The drug's clearance rate is 0.9 L/h/kg.
23
Roofie is a full agonist at the alpha-1 GABA-A receptor subunit.
24
Plasma levels of flunitrazepam peak at 4-7 ng/mL after 2 mg dose.
25
The drug has low aqueous solubility, aiding its use in powdered form.
26
Flunitrazepam's stereochemistry is achiral.
27
Roofie inhibits recombinant CYP2C19 with Ki=12 μM.
28
The compound has 3 hydrogen bond acceptors and 1 donor.
29
Flunitrazepam rotates plane-polarized light: [α]D = N/A (achiral).
30
Predicted logS for Roofie is -3.6.

04 · Category

Medical And Therapeutic Uses24 stats

01
Roofie was first synthesized in 1963 by Hoffman-La Roche.
02
Flunitrazepam is prescribed for severe insomnia unresponsive to other treatments.
03
Recommended dose for insomnia is 1-2 mg at bedtime.
04
In preoperative sedation, Roofie dose is 1-2 mg orally 45-60 min prior.
05
Flunitrazepam shortens sleep latency by 15-20 minutes on average.
06
Used in Europe for anesthesia induction at 0.02-0.08 mg/kg IV.
07
Clinical trials show 80% efficacy in treating transient insomnia.
08
Roofie increases total sleep time by 1.5-2 hours vs placebo.
09
In status epilepticus, IV flunitrazepam dose is 0.01-0.03 mg/kg.
10
Approved in over 60 countries for short-term hypnotic use.
11
Roofie reduces anxiety scores by 50% in preoperative patients.
12
Duration of hypnotic effect is 7-8 hours at 2 mg dose.
13
Used off-label for refractory seizures in children at 0.1 mg/kg/day.
14
Flunitrazepam improves sleep efficiency to 90% in insomniacs.
15
In ICU sedation, infusion rate is 0.1-0.2 mg/kg/h.
16
Roofie is contraindicated in myasthenia gravis patients.
17
Tolerance develops after 7-10 days of continuous use.
18
Withdrawal symptoms peak at 2-5 days post-discontinuation.
19
Elderly dose reduced to 1 mg max due to sensitivity.
20
Flunitrazepam enhances slow-wave sleep by 25%.
21
Used in veterinary medicine for sedation in large animals.
22
Oral absorption is rapid with Tmax of 0.5-3 hours.
23
Roofie not recommended beyond 4 weeks continuous use.
24
In 1990s, annual prescriptions in Europe exceeded 20 million.

05 · Category

Recreational And Illicit Use Statistics22 stats

01
Roofie involved in 1% of drug-facilitated assaults reported in US 1996-2000.
02
In 1990s, 1-2% of US college students reported lifetime Roofie use.
03
Street price of Roofie in US is $2-10 per tablet.
04
60% of seized Roofies in US are counterfeit containing other benzos.
05
Europe reports 0.5% prevalence of flunitrazepam use in general population.
06
In Australia, Roofie detections in wastewater peaked at 5 ng/L in 2018.
07
20% of club-goers in UK survey admitted knowing Roofie users.
08
US emergency dept visits involving Roofie rose 500% from 1994-1998.
09
Mexico is primary source for 90% of US Roofie supply.
10
1 in 5 sexual assaults on US campuses involve date rape drugs like Roofie.
11
Global illicit market for Roofie estimated at $50 million annually.
12
In Sweden, 10% of rapes in 1995-2004 involved flunitrazepam.
13
Roofie use in party scenes declined 70% post-1999 reformulation.
14
30% of seized tablets in Europe test positive for flunitrazepam.
15
US college rape reports with Roofie dropped 50% after 1998 scheduling.
16
In Brazil, 2% of nightlife attendees report Roofie exposure.
17
Forensic labs detect Roofie in 0.3% of toxicology cases yearly.
18
Roofie combined with alcohol in 80% of misuse cases.
19
Prevalence among US high school seniors: 1.6% lifetime use in 2001.
20
In Asia, Roofie trafficking seizures up 40% from 2015-2020.
21
15% of European festival drug tests positive for benzos including Roofie.
22
Roofie amnesia reported in 70% of overdose cases.
report visual · Comparison

Roofie Statistics statistics snapshot

Selected headline statistics from verified sources for a stable visual baseline.

40% of users experience next-day drowsiness.40%
Dependency risk after 4 weeks: 15-30%.-30%
Flunitrazepam causes respiratory depression in 25% of high-dose users.25%
Amnesia duration averages 8-12 hours post-ingestion.8
Paradoxical aggression occurs in 1-2% of patients.-2%
Overdose fatality rate with Roofie alone is low, <1%, but 10% with alcohol.1%
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Karl Becker. (2026, February 13). Roofie Statistics. Gitnux. https://gitnux.org/roofie-statistics
MLA
Karl Becker. "Roofie Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/roofie-statistics.
Chicago
Karl Becker. 2026. "Roofie Statistics." Gitnux. https://gitnux.org/roofie-statistics.

Sources & references

25 sources cited across this report

  1. pubchem.ncbi.nlm.nih.gov
  2. en.wikipedia.org
  3. drugbank.ca
  4. ebi.ac.uk
  5. ncbi.nlm.nih.gov
  6. drugs.com
  7. pubmed.ncbi.nlm.nih.gov
  8. medicines.org.uk
  9. nature.com
  10. pdsp.unc.edu
  11. ema.europa.eu
  12. roche.com
  13. dea.gov
  14. emcdda.europa.eu
  15. cdc.gov
  16. justice.gov
  17. unodc.org
  18. tga.gov.au
  19. gov.uk
  20. canada.ca
  21. accessdata.fda.gov
  22. legemiddelverket.no
  23. europol.europa.eu
  24. who.int
  25. incb.org